VRTX Overview

Key Data

  • Open $184.82
  • Day Range 181.02 - 185.22
  • 52 Week Range 176.36 - 242.99
  • Market Cap $47.14B
  • Shares Outstanding 254.25M
  • Public Float 252.62M
  • Beta 0.90
  • Rev. per Employee $1.826M
  • P/E Ratio 21.99
  • EPS $8.33
  • Yield N/A
  • Dividend N/A
  • Ex-Dividend Date N/A
  • Short Interest 4.76M 10/29/21
  • % of Float Shorted 1.88%
  • Average Volume 1.48M

Performance

5 Day
  • -2.29%
1 Month
  • -0.28%
3 Month
  • -6.56%
YTD
  • -22.57%
1 Year
  • -14.97%

Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 28 Full Ratings

Recent News

Vertex Pharmaceuticals started at market perform with $202 stock price target at BMO Capital

Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors

Defensive Stocks’ Time Is Coming. 3 Healthcare Firms to Consider.

Vertex Pharmaceuticals Inc. stock falls Wednesday, still outperforms market

Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day

Vertex Pharmaceuticals Inc. stock falls Monday, underperforms market

Vertex Pharmaceuticals Inc. stock rises Friday, outperforms market

Vertex Cystic Fibrosis Treatment Gets CHMP Backing in Patients Ages 6-11 >VRTX

Vertex Pharmaceuticals Inc. stock falls Thursday, underperforms market

Vertex Pharmaceuticals Inc. stock falls Wednesday, underperforms market

Vertex Pharmaceuticals Inc. stock falls Tuesday, underperforms market

Vertex Pharmaceuticals Inc. stock falls Monday, underperforms market

Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day

Vertex Pharmaceuticals Inc. stock rises Thursday, outperforms market

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Vertex Stock Is Climbing After Strong Earnings, but the Competition Hasn’t Gone Away.

Vertex Pharmaceuticals Inc. stock falls Tuesday, underperforms market

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Vertex Pharmaceuticals Inc. stock rises Thursday, still underperforms market

2 Beaten-Down Growth Stocks You Can Buy Right Now

on Motley Fool

CRISPR (CRSP) to Begin Clinical Study on Diabetes Therapy Drug

on Zacks.com

Great Point Partners Llc Buys BioAtla Inc, Dicerna Pharmaceuticals Inc, Vertex Pharmaceuticals ...

on GuruFocus.com

Copernicus Capital Management, LLC Buys Pfizer Inc, Thermo Fisher Scientific Inc, Teladoc ...

on GuruFocus.com

Twinbeech Capital Lp Buys The Estee Lauder Inc, TJX Inc, Wells Fargo, Sells Global Payments ...

on GuruFocus.com

2Xideas AG Buys IQVIA Holdings Inc, New York Times Co, Goosehead Insurance Inc, Sells S&P ...

on GuruFocus.com

Aristotle Atlantic Partners, LLC Buys ServiceNow Inc, Darling Ingredients Inc, Teleflex Inc, ...

on GuruFocus.com

Healthcare Value Capital, LLC Buys Vertex Pharmaceuticals Inc, Amryt Pharma PLC, Tyme ...

on GuruFocus.com

Caisse De Depot Et Placement Du Quebec Buys Lightspeed Commerce Inc, Electronic Arts Inc, ...

on GuruFocus.com

Lombard Odier Asset Management (USA) Corp Buys iShares Russell 2000 Growth ETF, BTC iShares ...

on GuruFocus.com

Lumina Fund Management LLC Buys Boeing Co, FedEx Corp, Humana Inc, Sells Alibaba Group Holding, ...

on GuruFocus.com

AIMZ Investment Advisors, LLC Buys AstraZeneca PLC, Vertex Pharmaceuticals Inc, Incyte Corp, ...

on GuruFocus.com

Loomis Sayles & Co L P Buys Vertex Pharmaceuticals Inc, Cummins Inc, T-Mobile US Inc, Sells ...

on GuruFocus.com

Holistic Financial Partners Buys iShares U.S. ...

on GuruFocus.com

Impax Asset Management Group plc Buys Microsoft Corp, United Rentals Inc, Texas Instruments ...

on GuruFocus.com

Roberts Glore & Co Inc Buys Vertex Pharmaceuticals Inc, AT&T Inc, S&P MidCap 400 ...

on GuruFocus.com

Stevens Capital Management Lp Buys The Energy Select Sector SPDR Fund, JPMorgan Chase, Health ...

on GuruFocus.com

The Key Behind Vertex's Great Q3 Results

on Motley Fool

3 Stocks Than Can Turn $10,000 Into $50,000 by 2025

on Motley Fool

Schwartz Investment Counsel Inc Buys Ardagh Metal Packaging SA, APi Group Corp, AptarGroup Inc, ...

on GuruFocus.com

Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals, Inc. is a global biotechnology company. It engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Competitors

Name Chg % Market Cap
AbbVie Inc. -0.77% $206.97B
Arcturus Therapeutics Holdings Inc. -1.14% $996.16M
Krystal Biotech Inc. 0.72% $1.11B
4D Molecular Therapeutics Inc. 0.78% $737.26M
Eloxx Pharmaceuticals Inc. -7.50% $66.33M
Competitor Data Provided ByCapital Cube Logo